Login
Navigate Fool.com
Will ARWR beat
the market?
Community Rating: 3 Stars: Appealing

12.77 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $12.90 $0.13 (1.02%)
Quote as of (NASDAQ)


company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.32
Previous Close $12.77
Daily Range $11.67 - $13.07
52-Week Range $1.65 - $27.63
Market Cap $578.8M
P/E Ratio -9.91
Dividend (Yield) $0.00 (0.0%)
Volume 2,834,121
Average Daily Volume 2,473,356
Current FY EPS -$0.80

How do you think ARWR
will perform against the market?

Top ARWR Bull/Bear Pitches

 

bodie17 (6.65)
Submitted July 2, 2010

New RNA thing.

0 Replies Reply Report this Post
 

alopex (< 20)
Submitted July 7, 2007

Wild mix of activities all aimed at attracting uncanny investors through broad band buzz-word bingo. Financials reflect that none of these areas are commercialized and probably will never be. Try to c … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

A $1 Trillion Drug Market?

That's what Arrowhead Research claims, but it should look at Gilead Sciences pricing in developing markets before spouting such inflated numbers.

Mid-Afternoon Market Update: Markets Trade Up as Bank of America Shares Remain Down

Mid-Day Market Update: Yahoo Jumps On Upbeat Results; ASML Shares Decline

Mid-Afternoon Market Update: Markets Trade in Highly Volatile Session as Talk of a Pull-Back is Wide

Mid-Afternoon Market Update: Markets Trade in Highly Volatile Session as Talk of a Pull-Back is Widespread

Why Arrowhead Research Corp. Shares Jumped

Arrowhead Research shares soar after it announces the completion of enrollment in its first cohort for a phase 2a trial. Can its shares move even higher?

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos

Although biotech in general has been having a rough go, these three stocks are falling like a knife.

Why Netflix, Arrowhead Research, and Trina Solar Tumbled Today

Stock markets overall didn't perform well Monday, but these stocks did even worse than the broader market. Find out why here.

Monday Sector Laggards: Biotechnology, Drugs

It's Official: Merck Now Owns Part of Alnylam

Alnylam (ALNY) has completed its acquisition of Merck's (MRK) RNAi business, handing over a 3% ownership stake in the company.

Despite skepticism, market technicals remain bullish

See More ARWR News...

Sector

Healthcare

Industry

Drugs

Arrowhead Research Corp (ARWR) Description

A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Website: http://www.arrowheadresearch.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks